Schrödinger

Sits at the seam between healthcare and software — computational drug discovery platform. Represented by Karen Akinsanya at Session I.

Key Points from SDDS 2026

• Co-founded the Ajax program (JAK2) — acquired by Lilly the morning of Session I
• SGR-1505: physics-discovered compound, asset to clinic-ready in 10 months
• Emphasis on the dynamic proteome: static structures are necessary but not sufficient
• The SARM1 case study (published with BMS in J. Med. Chem.) demonstrated cryptic pockets and dose-dependent biomarker reversal